Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN – Get Free Report) have been given an average recommendation of “Hold” by the ten brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $30.9250.
SNN has been the subject of a number of recent research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Monday. Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Zacks Research downgraded shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th.
Read Our Latest Stock Analysis on SNN
Smith & Nephew SNATS Stock Performance
Smith & Nephew SNATS Dividend Announcement
The company also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.
Hedge Funds Weigh In On Smith & Nephew SNATS
Several large investors have recently modified their holdings of SNN. BlackRock Inc. acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $505,323,000. River Road Asset Management LLC lifted its stake in Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after purchasing an additional 384,926 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after buying an additional 100,697 shares during the period. Bank of America Corp DE acquired a new stake in shares of Smith & Nephew SNATS in the second quarter valued at $97,223,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Smith & Nephew SNATS in the 2nd quarter valued at $89,325,000. Institutional investors and hedge funds own 25.64% of the company’s stock.
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Featured Stories
- Five stocks we like better than Smith & Nephew SNATS
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
